Drug companies raised the price of nearly 250 drugs since COVID-19 arrived in U.S.; 75 percent of those were drugs linked to COVID-19.
J&J and the rest of the pharmaceutical industry have seized on the coronavirus crisis as a way to polish an image tarnished by unaffordable medicine, patent lawsuits and an addiction epidemic.
"The price hike coincides with the company's push to get its drug to more patients — specifically those diagnosed with COVID-19."
The federal government will be the single largest investor and the largest purchaser of an upcoming COVID-19 vaccine or treatment.
New report shows an average increase of 5.6%
High prices not only pose a challenge to patient access, but they also raise a fundamental question: Are we creating these therapies the wrong way?